These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37833648)

  • 1. Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients.
    Zhou X; Weng Y; Jiang T; Ou W; Zhang N; Dong Q; Tang X
    BMC Cancer; 2023 Oct; 23(1):976. PubMed ID: 37833648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP.
    Dong Q; Ou W; Wang M; Jiang T; Weng Y; Zhou X; Tang X
    BMC Cancer; 2022 Sep; 22(1):988. PubMed ID: 36115970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of HDL cholesterol in anthracycline-induced subclinical cardiotoxicity: a prospective observational study in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Ou W; Jiang T; Zhang N; Lu K; Weng Y; Zhou X; Wang D; Dong Q; Tang X
    BMJ Open; 2024 Feb; 14(2):e074541. PubMed ID: 38341200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
    Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
    [No Abstract]   [Full Text] [Related]  

  • 5. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
    Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ
    Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
    Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
    J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
    Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study.
    Linares Ballesteros A; Sanguino Lobo R; Villada Valencia JC; Arévalo Leal O; Plazas Hernández DC; Aponte Barrios N; Perdomo Ramírez I
    Colomb Med (Cali); 2021 Feb; 52(1):e2034542. PubMed ID: 33911320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines.
    Bhagat AA; Kalogeropoulos AP; Baer L; Lacey M; Kort S; Skopicki HA; Butler J; Bloom MW
    J Pers Med; 2023 Dec; 13(12):. PubMed ID: 38138937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic value of global longitudinal strain combined with cardiac biomarkers on early detection of anthracycline-related cardiac dysfunction.
    Allam H; Kamal M; Bendary M; Osama A; El Eleimy HA; Bendary A
    J Echocardiogr; 2023 Dec; 21(4):165-172. PubMed ID: 37453981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.
    Mahjoob MP; Sheikholeslami SA; Dadras M; Mansouri H; Haghi M; Naderian M; Sadeghi L; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):74-83. PubMed ID: 31513000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
    Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
    Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
    Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia.
    Horacek JM; Pudil R; Tichy M; Jebavy L; Zak P; Slovacek L; Maly J
    Exp Oncol; 2007 Sep; 29(3):243-7. PubMed ID: 18004253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.